High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: Results from the European Group for Bone Marrow Transplantation

J. W. Sweetenham, R. Pearce, T. Philip, S. J. Proctor, F. Mandelli, P. Colombat, A. H. Goldstone

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The results of high-dose therapy and autologous BMT for patients with intermediate/high grade NHL were analysed in 82 patients aged ≥ 55 years, identified from the EBMT lymphoma database. These were compared with the results for 82 patients aged < 55 years who were matched on the basis of disease status at transplantation, presence of bone marrow or CNS involvement and closest date of transplantation. The 5 year actuarial progression-free survival (PFS) for patients aged < 55 years was 33% compared with 37% for the ≥ 55 year group (p = 0.08). Corresponding figures for overall survival (OS) were 39% and 38%, respectively (p = 0.19). No difference in outcome was observed according to histological subtype. Although the number of patients receiving total body irradiation (TBI) is small, a significantly lower PFS was observed in patients ≥ 55 years receiving TBI-based high-dose regimens compared with younger patients. This difference was due to a higher toxic death rate in the older patient group. In this retrospective matched analysis, age ≥ 55 years was not associated with lower PFS or OS following high-dose therapy and autologous BMT. The increased toxic death rate in patients receiving TBI suggests that this should be avoided in older patients, who should receive chemotherapy only in high-dose regimens.

Original languageEnglish (US)
Pages (from-to)981-987
Number of pages7
JournalBone Marrow Transplantation
Volume14
Issue number6
StatePublished - Dec 1 1994
Externally publishedYes

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Whole-Body Irradiation
Disease-Free Survival
Therapeutics
Poisons
Survival
Mortality
Lymphoma
Transplantation
Databases
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over : Results from the European Group for Bone Marrow Transplantation. / Sweetenham, J. W.; Pearce, R.; Philip, T.; Proctor, S. J.; Mandelli, F.; Colombat, P.; Goldstone, A. H.

In: Bone Marrow Transplantation, Vol. 14, No. 6, 01.12.1994, p. 981-987.

Research output: Contribution to journalArticle

@article{67471d4ea2f44230be5a13d1fdd8ac30,
title = "High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: Results from the European Group for Bone Marrow Transplantation",
abstract = "The results of high-dose therapy and autologous BMT for patients with intermediate/high grade NHL were analysed in 82 patients aged ≥ 55 years, identified from the EBMT lymphoma database. These were compared with the results for 82 patients aged < 55 years who were matched on the basis of disease status at transplantation, presence of bone marrow or CNS involvement and closest date of transplantation. The 5 year actuarial progression-free survival (PFS) for patients aged < 55 years was 33{\%} compared with 37{\%} for the ≥ 55 year group (p = 0.08). Corresponding figures for overall survival (OS) were 39{\%} and 38{\%}, respectively (p = 0.19). No difference in outcome was observed according to histological subtype. Although the number of patients receiving total body irradiation (TBI) is small, a significantly lower PFS was observed in patients ≥ 55 years receiving TBI-based high-dose regimens compared with younger patients. This difference was due to a higher toxic death rate in the older patient group. In this retrospective matched analysis, age ≥ 55 years was not associated with lower PFS or OS following high-dose therapy and autologous BMT. The increased toxic death rate in patients receiving TBI suggests that this should be avoided in older patients, who should receive chemotherapy only in high-dose regimens.",
author = "Sweetenham, {J. W.} and R. Pearce and T. Philip and Proctor, {S. J.} and F. Mandelli and P. Colombat and Goldstone, {A. H.}",
year = "1994",
month = "12",
day = "1",
language = "English (US)",
volume = "14",
pages = "981--987",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over

T2 - Results from the European Group for Bone Marrow Transplantation

AU - Sweetenham, J. W.

AU - Pearce, R.

AU - Philip, T.

AU - Proctor, S. J.

AU - Mandelli, F.

AU - Colombat, P.

AU - Goldstone, A. H.

PY - 1994/12/1

Y1 - 1994/12/1

N2 - The results of high-dose therapy and autologous BMT for patients with intermediate/high grade NHL were analysed in 82 patients aged ≥ 55 years, identified from the EBMT lymphoma database. These were compared with the results for 82 patients aged < 55 years who were matched on the basis of disease status at transplantation, presence of bone marrow or CNS involvement and closest date of transplantation. The 5 year actuarial progression-free survival (PFS) for patients aged < 55 years was 33% compared with 37% for the ≥ 55 year group (p = 0.08). Corresponding figures for overall survival (OS) were 39% and 38%, respectively (p = 0.19). No difference in outcome was observed according to histological subtype. Although the number of patients receiving total body irradiation (TBI) is small, a significantly lower PFS was observed in patients ≥ 55 years receiving TBI-based high-dose regimens compared with younger patients. This difference was due to a higher toxic death rate in the older patient group. In this retrospective matched analysis, age ≥ 55 years was not associated with lower PFS or OS following high-dose therapy and autologous BMT. The increased toxic death rate in patients receiving TBI suggests that this should be avoided in older patients, who should receive chemotherapy only in high-dose regimens.

AB - The results of high-dose therapy and autologous BMT for patients with intermediate/high grade NHL were analysed in 82 patients aged ≥ 55 years, identified from the EBMT lymphoma database. These were compared with the results for 82 patients aged < 55 years who were matched on the basis of disease status at transplantation, presence of bone marrow or CNS involvement and closest date of transplantation. The 5 year actuarial progression-free survival (PFS) for patients aged < 55 years was 33% compared with 37% for the ≥ 55 year group (p = 0.08). Corresponding figures for overall survival (OS) were 39% and 38%, respectively (p = 0.19). No difference in outcome was observed according to histological subtype. Although the number of patients receiving total body irradiation (TBI) is small, a significantly lower PFS was observed in patients ≥ 55 years receiving TBI-based high-dose regimens compared with younger patients. This difference was due to a higher toxic death rate in the older patient group. In this retrospective matched analysis, age ≥ 55 years was not associated with lower PFS or OS following high-dose therapy and autologous BMT. The increased toxic death rate in patients receiving TBI suggests that this should be avoided in older patients, who should receive chemotherapy only in high-dose regimens.

UR - http://www.scopus.com/inward/record.url?scp=0028588985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028588985&partnerID=8YFLogxK

M3 - Article

C2 - 7711677

AN - SCOPUS:0028588985

VL - 14

SP - 981

EP - 987

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -